036480.KQ Daesung Microbiological Labs. Co. Ltd
- Market cap
- KRW 20.9B
- P/E
- 59.8x
- P/B
- 0.60x
- ROE
- -3.7%
- Dividend yield
- 1.37%
- Fundamental score
- 2.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 036480.KQ undervalued?
Graham number036480.KQ trades 26.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Daesung Microbiological Labs. Co. Ltd fundamental analysis
11 of 21 checks passedROE 0/2
Low return on equity (-3.7%), below 10%.
ROA 0/1
Return on assets (-2.3%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (133.8%) is above the 5-year average (-17.0% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (133.8%) is above the industry median (1.8%).
Revenue Growth 1/2
Revenue grew 0.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (43.2%), up to 100%.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 2/2
Loss-making but free cash flow is positive.
PE vs Market 0/1
PE (59.8x) is above the market median (11.3x).
PE vs Industry 0/1
PE (59.8x) is above the industry median (11.4x).
PBV 1/1
Price to book (0.6x) is below the industry median (0.9x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 36.2, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (1.4%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 47.6%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Daesung Microbiological Labs. Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Daesung Microbiological Labs. Co. Ltd
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in Uiwang-si, South Korea.
Full company profileDaesung Microbiological Labs. Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Daesung Microbiological Labs. Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 30.8B | 24.0B | 25.1B | 25.1B | 24.8B | 24.0B | 25.5B | 25.6B | 23.8B | 26.0B | 22.2B |
| Gross Profit | 10.2B | 7.23B | 8.23B | 8.44B | 8.04B | 5.74B | 4.79B | 4.85B | 4.05B | 6.44B | 3.39B |
| Operating Income | 4.95B | 1.99B | 3.41B | 3.38B | 1.92B | 337M | -328M | -689M | -1.55B | 714M | -1.98B |
| EBITDA | - | - | - | - | - | - | 5.48B | 2.67B | 990M | 3.48B | 1.80B |
| Net Income | 4.49B | 1.56B | 3.17B | 2.85B | 1.52B | 866M | 1.70B | -680M | -1.77B | 598M | -1.29B |
| EPS | 1,183 | 410 | 834 | 750 | 400 | 228 | 448 | -179 | -466 | 157 | -339 |
| Balance Sheet | |||||||||||
| Total Assets | 35.6B | 34.8B | 38.1B | 50.8B | 62.3B | 62.6B | 65.1B | 64.3B | 58.4B | 58.0B | 57.2B |
| Total Liabilities | 6.60B | 4.49B | 5.09B | 15.7B | 26.0B | 25.6B | 26.3B | 26.9B | 23.2B | 22.6B | 22.7B |
| Shareholders' Equity | 29.0B | 30.3B | 33.0B | 35.1B | 36.3B | 37.0B | 38.8B | 37.3B | 35.1B | 35.4B | 34.5B |
| Cash & Short-term Investments | 9.90B | 9.17B | 11.2B | 12.5B | 10.1B | 9.93B | 12.9B | 11.7B | 9.05B | 3.45B | 2.84B |
| Total Debt | 1.14B | 925M | - | 11.8B | 21.7B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.52B | 1.68B | 3.14B | 2.32B | 3.24B | 2.20B | 1.16B | -1.23B | 2.10B | 1.41B | 1.25B |
| Capital Expenditure | 948M | 1.13B | 423M | 11.4B | 14.0B | 2.97B | 2.32B | 1.26B | 796M | 358M | 377M |
| Free Cash Flow | - | - | - | -11.2B | -11.2B | -766M | -1.16B | -2.49B | 1.31B | 1.05B | 876M |
| Ratios | |||||||||||
| ROE | 15.5% | 5.1% | 9.6% | 8.1% | 4.2% | 2.3% | 4.4% | -1.8% | -5.0% | 1.7% | -3.7% |
| ROA | 12.6% | 4.5% | 8.3% | 5.6% | 2.4% | 1.4% | 2.6% | -1.1% | -3.0% | 1.0% | -2.3% |
| Net Profit Margin | 14.6% | 6.5% | 12.6% | 11.3% | 6.1% | 3.6% | 6.7% | -2.7% | -7.4% | 2.3% | -5.8% |
| Debt to Equity | 0.04x | 0.03x | - | 0.34x | 0.60x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Daesung Microbiological Labs. Co. Ltd dividends
- Dividend yield
- 1.37%
- Forward dividend
- 75.00 KRW
- Payout ratio
- 47.6%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 285M | 75 | 47.6% |
| 2024 | KRW 285M | 75 | - |
| 2023 | KRW 285M | 75 | - |
| 2022 | KRW 285M | 75 | 16.7% |
| 2021 | KRW 323M | 85 | 37.3% |
| 2020 | KRW 323M | 85 | 21.3% |
| 2019 | KRW 323M | 85 | 11.3% |
| 2018 | KRW 323M | 85 | 10.2% |
| 2017 | KRW 380M | 100 | 24.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10:1 on May 16, 2018.
Who owns Daesung Microbiological Labs. Co. Ltd
- Insiders 39.60%
- Institutions 0.00%
- Public & others 60.40%
- Shares outstanding 3.80M
- Free float 2.30M
Daesung Microbiological Labs. Co. Ltd company profile
- Company name
- Daesung Microbiological Labs. Co. Ltd
- Ticker
- 036480.KQ
- ISIN
- KR7036480002
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Fiscal year end
- December
- Address
- 103, Deogyeong-Daero, Uiwang-si, South Korea
- Phone
- 82 3 1461 7103
- Website
- dsmbio.co.kr
About Daesung Microbiological Labs. Co. Ltd
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in Uiwang-si, South Korea.
Daesung Microbiological Labs. Co. Ltd management
2- Seunghoon ChoiCEO & Representative Director · born 1968
- Mr. Dong-Jik LeeExecutive Director · born 1954